Laporan Laba Rugi (TTM)
Laporan Laba Rugi Genix Pharmaceuticals Corporation menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2023 01-31 |
2023 04-30 |
2023 07-31 |
2023 10-31 |
2024 01-31 |
2024 04-30 |
2024 07-31 |
2024 10-31 |
2025 01-31 |
2025 04-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 510.94 | 27.75 | 0.00 | -12.24 | -47.71 | -29.70 | 1.71 | -1.75 | -73.19 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 1,042.80 | 5.01 | 0.00 | -8.19 | -78.93 | -4.27 | 10,883.59 | -0.01 | -0.71 | |
| % of Revenue | 47.85 | 89.51 | 73.57 | 73.57 | 76.97 | 31.01 | 42.23 | 4,560.45 | 4,641.48 | 17,190.25 |
| Gross Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 |
| Change (%) | 22.91 | 221.79 | 0.00 | -23.51 | 56.61 | -41.14 | -7,952.80 | 0.03 | 0.89 | |
| % of Revenue | 52.15 | 10.49 | 26.43 | 26.43 | 23.03 | 68.99 | 57.77 | -4,460.45 | -4,541.48 | -17,090.25 |
| SG&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -1.53 | -18.67 | 8.40 | -15.09 | -13.28 | 7.84 | -20.23 | -5.39 | -4.98 | |
| % of Revenue | 20,946.21 | 3,375.96 | 2,149.22 | 2,329.85 | 2,254.08 | 3,738.56 | 5,735.38 | 4,498.27 | 4,331.63 | 15,352.58 |
| R&D | ||||||||||
| Change (%) | ||||||||||
| % of Revenue | ||||||||||
| OpEx | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -0.16 | -7.43 | 2.29 | -21.56 | -26.60 | -24.51 | 0.33 | -2.67 | -2.76 | |
| % of Revenue | 56,441.15 | 9,223.81 | 6,683.96 | 6,837.05 | 6,110.50 | 8,577.37 | 9,211.47 | 9,086.67 | 9,001.56 | 32,648.92 |
| Operating Income | -1 | -1 | -1 | -1 | -1 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | -1.07 | -7.81 | 2.33 | -21.70 | -26.25 | -24.45 | 0.31 | -2.68 | -1.97 | |
| % of Revenue | -56,341.15 | -9,123.81 | -6,583.96 | -6,737.05 | -6,010.50 | -8,477.37 | -9,111.47 | -8,986.67 | -8,901.56 | -32,548.92 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | 37.44 | 25.60 | 71.42 | 32.08 | 29.78 | 25.83 | 9.06 | 13.08 | 10.05 | |
| % of Revenue | -1,088.94 | -244.98 | -240.86 | -412.88 | -621.36 | -1,542.18 | -2,760.38 | -2,959.81 | -3,406.76 | -13,984.35 |
| Net Income | -1 | -1 | -1 | -4 | -4 | -4 | -4 | -0 | -0 | -0 |
| Change (%) | 0.68 | -9.11 | 399.06 | -3.82 | -3.50 | -2.01 | -98.17 | 65.85 | -27.98 | |
| % of Revenue | -60,843.17 | -10,026.28 | -7,133.53 | -35,600.34 | -39,014.35 | -72,000.00 | -100,366.41 | -1,806.86 | -3,050.05 | -8,193.91 |
Source: Capital IQ
